Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1525-1530

  Hahn, Noah M ^{a,b,c,d,e,f,g,h}   Stadler, Walter M ^{a,b,c,d,e,f,g,h}   Zon, Robin T ^{a,b,c,d,e,f,g,h}   Waterhouse, David ^{a,b,c,d,e,f,g,h}   Picus, Joel ^{a,b,c,d,e,f,g,h}   Nattam, Sreenivasa ^{a,b,c,d,e,f,g,h}   Johnson, Cynthia S ^{a,b,c,d,e,f,g,h}   Perkins, Susan M ^{a,b,c,d,e,f,g,h}   Waddell, Mary Jane ^{a,b,c,d,e,f,g,h}   Sweeney, Christopher J ^{a,b,c,d,e,f,g,h}  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Northern Indiana Cancer Research Consortium   (United States)

^d Fort Wayne Oncology and Hematology Inc   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Oncology Hematology Care   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE;

ADULT; AGED; ANEMIA; AORTA DISSECTION; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79955006416     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.6067     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
3. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005 (Pubitemid 46224062)
4. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
5. Folkman J: Tumor angiogenesis: A possible control point in tumor growth. Ann Intern Med 82:96-100, 1975
6. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 46:467-473, 1986 (Pubitemid 16145386)
7. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
8. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739, 2002 (Pubitemid 37328908)
9. Fauconnet S, Bernardini S, Lascombe I, et al: Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncol Rep 21:1495-1504, 2009
10. Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22:1-6, 2004
11. Kong C, Zhu Y, Sun C, et al: Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 65:395-399, 2005 (Pubitemid 40248049)
12. Sonpavde G, Jian W, Liu H, et al: Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27:391-399, 2009
13. Zhang X, Yamashita M, Uetsuki H, et al: Short-term effects of TNP-470 in combination with cisplatin in the rat model of bladder cancer. In Vivo 16:293-297, 2002 (Pubitemid 35460379)
14. Bellmunt J, Gonzalez-Larriba JL, Maroto JP, et al: First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. J Clin Oncol 28:351s, 2010 (suppl; abstr 4540)
15. Gallagher DJ, Milowsky MI, Gerst SR, et al: Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28:1373-1379, 2010
16. Shih T, Lindley C: Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779-1802, 2006 (Pubitemid 46038527)
17. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, doubleblind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
18. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
19. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
20. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
21. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
22. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
23. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
24. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Jennison C, Turnbull BW: Confidence intervals for a binomial parameter following a multi-stage test with application to MIL-STC 105D and medical trials. Technometrics 25:49-58, 1983 (Pubitemid 13487876)
27. Zielinski CC, Schnack B, Grbovic M, et al: Paclitaxel and carboplatin in patients with metastatic urothelial cancer: Results of a phase II trial. Br J Cancer 78:370-374, 1998 (Pubitemid 28336425)
28. Li J, Juliar B, Yiannoutsos C, et al: Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study. J Clin Oncol 23:1185-1191, 2005 (Pubitemid 46202275)
29. Sternberg CN, de Mulder PH, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 19:2638-2646, 2001 (Pubitemid 32441368)
30. Galsky MD, Iasonos A, Mironov S, et al: Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109:549-555, 2007 (Pubitemid 46190963)
31. Bellmunt J, von der Maase H, Mead GM, et al: Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy: EORTC30987/Intergroup Study. J Clin Oncol 25:242s, 2007 (suppl; abstr LBA5030)
32. Bajorin DF, McCaffrey JA, Hilton S, et al: Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial. J Clin Oncol 16:2722-2727, 1998 (Pubitemid 28363036)
33. Amgen: Aranesp (darbepoetin alfa) for injection package insert. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/ HowDrugsareDeveloped andApproved/ApprovalApplications/TherapeuticBiologic Applications/ucm086048.pdf
34. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008 (Pubitemid 351397066)
35. Launay-Vacher V, Janus N, Spano J, et al: Impact of renal insufficiency on cancer survival: Results of the IRMA-2 study. J Clin Oncol 27:504s, 2009 (suppl; abstr 9585)
36. Gray R, Bhattacharya S, Bowden C, et al: Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972, 2009
37. Alfaro C, Suarez N, Gonzalez A, et al: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100:1111-1119, 2009
38. Osada T, Chong G, Tansik R, et al: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57:1115-1124, 2008
39. Ghadjar P, Burkhard FC, Gautschi O, et al: Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int 10.1111/j.1464- 410X.2010.09574.x [epub ahead of print on September 14, 2010]
40. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
41. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27:1227-1234, 2009
42. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
43. Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239, 2007 (Pubitemid 47299901)
44. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237, 2009
45. Bruns CJ, Solorzano CC, Harbison MT: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-2935, 2000 (Pubitemid 30395817)
46. Kaushal V, Kohli M, Zangari M, et al: Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol 20:3042, 2002
47. Kuenen BC, Rosen L, Smit EF, et al: Dosefinding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657-1667, 2002 (Pubitemid 34260548)
48. Togna GI, Togna AR, Franconi M: Cisplatin triggers platelet activation. Thromb Res 99:503-509, 2000
49. Apolo AB, Regazzi AM, Milowsky MI, et al: Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab. J Clin Oncol 27:252s, 2009 (suppl; abstr 5074)